Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Study shows long-term benefits

Vaccination: protection beyond infection

Vaccination not only prevents disease caused by acute infection: it also protects against long-term immune-related consequences that can follow an acute viral infection, a new study finds.

News • Pooled TB testing strategy

Tuberculosis: Rapid low-cost diagnosis within reach for ‘missed millions’

Global efforts to tackle tuberculosis are hampered by the large number who remain undiagnosed, untreated and unknowingly spreading TB. A new study proposes a rapid diagnosis workflow to fix this.

News • Medical mycology

Faster diagnosis for fungal bloodstream infections

Fungal bloodstream infections can be life-threatening. In a recent study, researchers developed a new workflow to identify fungal species in blood samples much faster than conventional methods.

Related articles